Working... Menu
Trial record 33 of 724 for:    Botulinum Toxins, Type A

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01124565
Recruitment Status : Completed
First Posted : May 17, 2010
Last Update Posted : January 17, 2014
Information provided by (Responsible Party):
Revance Therapeutics, Inc.

Brief Summary:
This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.

Condition or disease Intervention/treatment Phase
Lateral Canthal Lines Crow's Feet Facial Wrinkles Drug: RT001 Phase 2

Detailed Description:
Revance is conducting this Phase 2 clinical study to establish the safety of two (2) sequential doses of RT001 Topical Gel at Baseline (Day 0) and Week 4 for the treatment of moderate to severe LCLs at rest.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Repeat Dose, Multi-Center Study to Evaluate the Safety of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Study Start Date : May 2010
Actual Primary Completion Date : July 2010
Actual Study Completion Date : July 2010

Arm Intervention/treatment
Experimental: RT001
RT001 (Botulinum Toxin Type A) Topical Gel
Drug: RT001
RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas

Primary Outcome Measures :
  1. Assessment of treatment-emergent adverse events based on safety assessments. [ Time Frame: 4 weeks and 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Written informed consent including authorization to release health information
  • Female or male, 18 to 65 years of age and in good general health
  • Willing and able to follow study instructions and likely to complete all study requirements
  • Moderate to severe lateral canthal lines (crow's feet wrinkles)

Exclusion Criteria:

  • Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis
  • Muscle weakness or paralysis, particularly in the area receiving study treatment
  • Active disease or irritation at the treatment areas including the eye and the skin
  • Pregnant, nursing, or planning a pregnancy during the study; or is a woman of child bearing potential (WOCBP) but is not willing to use an effective method of birth control
  • Previous participation in a RT001 clinical study
  • Previous treatment with botulinum toxin (any serotype)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01124565

Layout table for location information
United States, Alabama
Total Skin & Beauty Dermatology Center, PC
Birmingham, Alabama, United States, 35205
United States, California
Therapeutics Clinical Research
San Diego, California, United States, 92123
United States, Nebraska
Skin Specialists, PC
Omaha, Nebraska, United States, 68144
Sponsors and Collaborators
Revance Therapeutics, Inc.
Layout table for investigator information
Principal Investigator: Joel Schlessinger, M.D. Skin Specialists, PC

Layout table for additonal information
Responsible Party: Revance Therapeutics, Inc. Identifier: NCT01124565     History of Changes
Other Study ID Numbers: RT001-CL025LCL
First Posted: May 17, 2010    Key Record Dates
Last Update Posted: January 17, 2014
Last Verified: December 2013

Keywords provided by Revance Therapeutics, Inc.:
Lateral Canthal Lines
Crow's Feet
Facial Wrinkles

Additional relevant MeSH terms:
Layout table for MeSH terms
Botulinum Toxins, Type A
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents